Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07380659
PHASE1

Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

View on ClinicalTrials.gov

Summary

To study the safety and efficacy of fibroblast activation protein (FAP)-targeted allogeneic immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of acute myocardial infarction with cardiogenic shock and provide a new method for the treatment of acute myocardial infarction with cardiogenic shock.

Official title: Safety and Efficacy of Allogeneic Immunosuppressive CAR-DC Targeting FAP in the Treatment of Acute Myocardial Infarction With Cardiogenic Shock

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2026-01-20

Completion Date

2027-02-28

Last Updated

2026-02-02

Healthy Volunteers

No

Interventions

BIOLOGICAL

FAP allogeneic immunosuppressive CAR-DC

Each subject receive FAP immunosuppressive CAR-DC by intravenous infusion at the first day of shock.

Locations (1)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China